Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 

Prevalence and Incidence of Osteopetrosis autosomal dominant type 2

Osteopetrosis autosomal dominant type 2: Rare Disease

Osteopetrosis autosomal dominant type 2 is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that Osteopetrosis autosomal dominant type 2, or a subtype of Osteopetrosis autosomal dominant type 2, affects less than 200,000 people in the US population.

Ophanet, who are a consortium of European partners, currently defines a condition rare when if affects 1 person per 2,000. They list Osteopetrosis autosomal dominant type 2 as a "rare disease". More information about Osteopetrosis autosomal dominant type 2 is available from Orphanet

About prevalence and incidence statistics:

The term 'prevalence' of Osteopetrosis autosomal dominant type 2 usually refers to the estimated population of people who are managing Osteopetrosis autosomal dominant type 2 at any given time. The term 'incidence' of Osteopetrosis autosomal dominant type 2 refers to the annual diagnosis rate, or the number of new cases of Osteopetrosis autosomal dominant type 2 diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise